These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 27390342

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
    Moon SJ, Jeong BC, Kim HJ, Lim JE, Kim HJ, Kwon GY, Jackman JA, Kim JH.
    Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer.
    Hou X, Li Z, Huang W, Li J, Staiger C, Kuang S, Ratliff T, Liu X.
    Prostate; 2013 Sep; 73(12):1352-63. PubMed ID: 23661607
    [Abstract] [Full Text] [Related]

  • 6. High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.
    Jansson KH, Tucker JB, Stahl LE, Simmons JK, Fuller C, Beshiri ML, Agarwal S, Fang L, Hynes PG, Alilin AN, Lake R, Abbey YC, Cawley J, Tice CM, Yin J, McKnight C, Klummp-Thomas C, Zhang X, Guha R, Hoover S, Simpson RM, Nguyen HM, Corey E, Thomas CJ, Proia DA, Kelly K.
    Sci Rep; 2018 Nov 22; 8(1):17239. PubMed ID: 30467317
    [Abstract] [Full Text] [Related]

  • 7. Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy.
    Liao Y, Liu Y, Xia X, Shao Z, Huang C, He J, Jiang L, Tang D, Liu J, Huang H.
    Theranostics; 2020 Nov 22; 10(8):3366-3381. PubMed ID: 32206096
    [Abstract] [Full Text] [Related]

  • 8. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
    Lamoureux F, Thomas C, Yin MJ, Fazli L, Zoubeidi A, Gleave ME.
    Eur Urol; 2014 Jul 22; 66(1):145-55. PubMed ID: 24411988
    [Abstract] [Full Text] [Related]

  • 9. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.
    Lallous N, Leblanc E, Munuganti RS, Hassona MD, Nakouzi NA, Awrey S, Morin H, Roshan-Moniri M, Singh K, Lawn S, Yamazaki T, Adomat HH, Andre C, Daugaard M, Young RN, Guns ES, Rennie PS, Cherkasov A.
    Mol Cancer Ther; 2016 Dec 22; 15(12):2936-2945. PubMed ID: 27765852
    [Abstract] [Full Text] [Related]

  • 10. Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.
    Lakshmana G, Baniahmad A.
    Int J Cancer; 2019 Apr 15; 144(8):1775-1779. PubMed ID: 30125354
    [Abstract] [Full Text] [Related]

  • 11. Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.
    Li J, Wang R, Kong Y, Broman MM, Carlock C, Chen L, Li Z, Farah E, Ratliff TL, Liu X.
    Mol Cancer Ther; 2017 Mar 15; 16(3):469-479. PubMed ID: 28069876
    [Abstract] [Full Text] [Related]

  • 12. Design, Synthesis, and Biological Evaluation of Androgen Receptor (AR) Antagonist-Heat Shock Protein 90 (Hsp90) Inhibitor Conjugates for Targeted Therapy of Castration-Resistant Prostate Cancer.
    Zhang S, Meng X, Zhang S, Li B, Jin W, Zhang C, Liu Z, Hu X, Ge L, Yu Z, Li Z, Ma S, Wang X, Li L, Qin C.
    J Med Chem; 2023 Apr 13; 66(7):4784-4801. PubMed ID: 36960664
    [Abstract] [Full Text] [Related]

  • 13. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.
    He S, Zhang C, Shafi AA, Sequeira M, Acquaviva J, Friedland JC, Sang J, Smith DL, Weigel NL, Wada Y, Proia DA.
    Int J Oncol; 2013 Jan 13; 42(1):35-43. PubMed ID: 23152004
    [Abstract] [Full Text] [Related]

  • 14. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.
    Gandhi N, Wild AT, Chettiar ST, Aziz K, Kato Y, Gajula RP, Williams RD, Cades JA, Annadanam A, Song D, Zhang Y, Hales RK, Herman JM, Armour E, DeWeese TL, Schaeffer EM, Tran PT.
    Cancer Biol Ther; 2013 Apr 13; 14(4):347-56. PubMed ID: 23358469
    [Abstract] [Full Text] [Related]

  • 15. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth.
    Cha TL, Qiu L, Chen CT, Wen Y, Hung MC.
    Cancer Res; 2005 Mar 15; 65(6):2287-95. PubMed ID: 15781642
    [Abstract] [Full Text] [Related]

  • 16. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.
    Centenera MM, Carter SL, Gillis JL, Marrocco-Tallarigo DL, Grose RH, Tilley WD, Butler LM.
    Endocr Relat Cancer; 2015 Oct 15; 22(5):805-18. PubMed ID: 26187127
    [Abstract] [Full Text] [Related]

  • 17. Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer.
    Li J, Karki A, Hodges KB, Ahmad N, Zoubeidi A, Strebhardt K, Ratliff TL, Konieczny SF, Liu X.
    Mol Cell Biol; 2015 Dec 15; 35(24):4185-98. PubMed ID: 26438599
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Berberine suppresses androgen receptor signaling in prostate cancer.
    Li J, Cao B, Liu X, Fu X, Xiong Z, Chen L, Sartor O, Dong Y, Zhang H.
    Mol Cancer Ther; 2011 Aug 15; 10(8):1346-56. PubMed ID: 21613449
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.